Many patients have not been offered potentially curative allogeneic marrow transplants because of the toxicity of myeloablative regimens in the setting of advanced age or organ dysfunction. We treated five patients, ineligible for myeloablative chemotherapy due to one of these criteria, with fludarabine-based nonmyeloablative chemotherapy followed by reinfusion of G-CSF-mobilised allogeneic peripheral blood progenitor cells (PBPC). Two patients died early of multi-organ failure. Another patient with massive splenomegaly was infused with a suboptimal number of PBPC; no engraftment was documented. The remaining two patients demonstrated mixed chimerism early posttransplant, but by 3 and 6 months respectively, engraftment was almost entirely of donor origin. One of these patients, transplanted with relapsed AML, remains in remission with extensive chronic GVHD at 17 months. The other patient, transplanted with chemorefractory mantle cell lymphoma, progressed early posttransplant but entered remission coincident with the onset of severe GVHD following cessation of cyclosporin A, suggesting a powerful graft-versus-mantle cell lymphoma effect. These preliminary observations suggest this approach results in engraftment and GVHD/graftversus-tumour effects similar to myeloablative regimens and may provide an alternative in patients ineligible for conventional conditioning regimens.
versus-tumour effects are powerful enough to eradicate haematological malignancies in the absence of intensive chemotherapy.
1 DLI is given without further GVHD prophylaxis, on the basis that the recipient has developed a degree of tolerance to allogeneic donor cells. In patients with chronic myeloid leukaemia, DLI is most effective in patients with early relapse, 2 suggesting that disease burden is an important determinant of outcome and that prior cytoreductive chemotherapy in advanced disease may be of benefit.
With this background, Giralt and colleagues 3 developed a strategy using purine analog-containing non-myeloablative preparative regimens to facilitate engraftment of HLA-compatible peripheral blood progenitor cells (PBPC). This approach exploits the profound immunosuppressive capacity of the purine analogs. They reasoned that if donor engraftment could be at least partially established, any resulting graft-versus-tumour effect may, in the context of partial tumour debulking by these regimens, be sufficiently potent to eradicate any remaining disease. Their preliminary experience involved 15 patients with acute myeloid leukaemia or myelodysplasia, 12 of whom were refractory to therapy or beyond first relapse. All were ineligible for conventional myeloablative therapy because of older age or organ dysfunction. They demonstrated that partial donor engraftment was achievable, although post-transplant follow-up was relatively short. Of the 15 patients treated, 11 relapsed and only one was alive in complete remission (CR) more than 2 months post-transplant.
We report our preliminary experience in five patients utilising a treatment approach based on similar principles. We demonstrate that donor cells may have an engraftment advantage in this setting, donor engraftment appears durable, and that the graft-versus-host (and probably graft-versus-tumour) effect of donor cells is preserved. Table 1 outlines patient and disease characteristics, and outcome. Conventional myeloablative chemotherapy was contraindicated in each instance, either on the basis of patient age, extent of prior treatment or organ dysfunction. The three patients (cases 1-3) with leukaemia received conditioning with fludarabine (30 mg/m 2 d −7 to d −3 inclusive), cytosine arabinoside (2 g/m 2 over 4 h day −7 to day −3, 4 h post-fludarabine) and granulocyte colony- stimulating factor (filgrastim 5 g/kg subcutaneously day −8 to day −3). 4 The two patients with non-Hodgkin's lymphoma (NHL) (cases 4 and 5) received conditioning with fludarabine (30 mg/m 2 day −3, day −2), cytosine arabinoside (500 mg/m 2 day −3, day −2, 4 h post-fludarabine) and cisplatin (25 mg/m 2 daily as a continuous infusion day −5 to day −2).
Patients and methods

5
All patients then received filgrastim-mobilised (10 g/kg/day) PBPC from HLA-identical sibling donors, with the first leukapheresis (10 l processed) on day 5 after four injections. The intention was to infuse a minimum of 3 × 10 6 CD34-positive PBPC/kg recipient, from a maximum of two collections per donor. PBPC were infused 2 days after the end of chemotherapy if one collection was performed; if two were performed, the first was kept at 4°C for 24 h and infused with the second collection. The day of infusion was designated day zero (d 0). All patients received cyclosporin A (CsA) 3 mg/kg/day and shortcourse methotrexate (15 mg/m 2 day 1, 10 mg/m 2 days 3 and 6) as GVHD prophylaxis. Filgrastim 5 g/kg was given daily from day 7 post-infusion to neutrophil recovery. The study was approved by the institutional review board and all patients gave written informed consent.
The age of the donors ranged between 37 and 63 years; four were aged more than 50 years ( Table 1 ). The median number of CD34-positive cells collected per leukapheresis was 1.1 × 10 6 /kg recipient weight (range 0.24-3.4). Three patients were infused with fewer than 3 × 10 6 CD34/kg (two р1.2 × 10 6 CD34/kg) due to donor refusal to undergo a second collection in one case, and poor yields despite two leukaphereses in the other two. Neutrophil and platelet engraftment (Ͼ0.5 and Ͼ20 × 10 9 /l, respectively) occurred a median of 15.5 (14-17) and 19.5 (15-21) days respectively post-PBPC infusion in the four evaluable patients.
Two patients died early post-transplant. Case 2 was transplanted for relapsed acute leukaemia; previous induction chemotherapy had been complicated by liver dysfunction and pneumonia. She was febrile and neutropenic on admission and the transplant course was complicated by neutropenic enterocolitis and progressive hyperbilirubinaemia and pneumonia. A post-mortem was not performed after her death on day 17. Case 4 developed cardiac failure on day 6 complicated by pneumonia; she died of cardiorespiratory failure on day 31. Post-mortem showed a normocellular marrow, cardiomegaly, pulmonary congestion and micronodular cirrhosis; there was no evidence of viable lymphoma.
Case 2 died before evidence of count recovery; a peripheral blood sample on day 14 yielded insufficient DNA for molecular analysis. Chimerism studies were not performed in case 4. Chimerism was evaluated in the remaining three patients (cases 1, 3 and 5), one of whom was sex mismatched (case 5). Mixed chimerism was demonstrated in case 5 by standard karyotyping in the first month post-transplant; using fluorescent in situ hybridisation analysis, less than 1% of marrow cells were of recipient origin at day 80. Chimerism in the other two evaluable patients was determined by amplifying the hypervariable region lying 3′ to the apolipoprotein B (apoB) gene. Genomic DNA was extracted from bone marrow and subjected to polymerase chain reaction using oligonucleotides flanking the 3′ region of the apoB gene.
7 Figure 1 shows recipient and donor pat- terns for the apoB locus prior to transplantation in case 1. Recipient DNA persisted on days 31, 71 and 140 posttransplant, but on days 181, 244 and 337 (data for day 337 not shown) only donor DNA could be detected. No donor engraftment was demonstrable in case 3; this patient had massive splenomegaly and was re-infused with a sub-optimal number of PBPC.
Discussion
Our preliminary experience provides three complementary observations to the Giralt report. Firstly, mobilisation of PBPC was suboptimal in this predominantly older group of donors. This contrasts with the effective mobilisation using the same regimen in a younger group of normal volunteers at this institution 8 and is also at variance with the mobilisation observed by Giralt in a similarly aged donor group. While the latter may be partly explained by differences in assay technique, it is possible that the dose and schedule of filgrastim administration used by Giralt (6 g/kg twice daily) is more effective. Based on our initial results, we have elected to use a higher, but generally well tolerated, filgrastim dose (16 g/kg) in the next cohort of donors. 9 Secondly, our first case demonstrates that this approach can result in durable engraftment of donor cells, and that mixed chimerism early post-transplant does not preclude the eventual establishment of predominantly donor haematopoiesis. Nevertheless, the failure of engraftment in case 3 suggests that in patients with packed marrow and/or bulky splenomegaly, more intensive debulking chemotherapy and the infusion of large numbers of stem cells should be considered. In contrast to the other patients who had all received multiple cycles of combination chemotherapy, this patient had not had prior chemotherapy other than hydroxyurea. It is possible that this relative lack of intensive treatment resulted in more resistance to engraftment.
Thirdly, it is clear that the donor cells have the potential to cause significant ongoing GVHD. In the Giralt study, in which GVHD prophylaxis consisted of CsA and methylprednisolone, acute GVHD occurred in three of 13 evaluable patients (all рgrade 2) and chronic GVHD did not occur in five evaluable patients, although with relatively short follow-up. The first patient in our study developed significant acute GVHD, despite prophylaxis with both CSA and methotrexate, and requires ongoing treatment with CSA and prednisolone for extensive chronic GVHD. Moreover, the prolonged duration of second remission in this patient after a single course of chemotherapy for relapsed AML suggests that the donor cells may exert a clinically relevant graft-versus-leukemia (GVL) effect.
The sequence of events in case 5 is also strongly suggestive of a graft-versus-lymphoma effect. One month posttransplant, the patient had unequivocal CT scan evidence of progressive bulky abdominal disease together with lymphomatous pleural encasement and pleural effusions containing CD5-positive lymphoma cells bearing the t(11;14) translocation. A single course of dexamethasone 40 mg daily for 4 days was begun on day 45. Reassessment at day 80, 2 weeks after the onset of severe GVHD, demonstrated substantial resolution of the abdominal lymphadenopathy and pleural thickening; pleural fluid cytology and flow cytometry showed no evidence of lymphoma at day 102. He died on day 110 of disseminated aspergillus; at postmortem there was no histological evidence of residual disease. We believe this is the first case in which a graftversus-mantle cell lymphoma effect has been reported.
Thus far, the results of this experimental approach in terms of patient survival have been poor, most likely reflecting its application in elderly and/or heavily pretreated patients with advanced disease. Giralt and colleagues 3 observed a very high relapse rate in their high-risk patients and two of the five patients in our series died of multi-organ failure within a month of the transplant, despite the use of relatively non-toxic chemotherapy. We suggest that this treatment may not be appropriate for patients with multiple organ dysfunction or chemorefractory or multiplyrelapsed leukaemia, and that careful patient selection will be required for this approach to be beneficial. Nevertheless, we have been sufficiently encouraged by these preliminary observations to enroll additional patients on study, and have expanded eligibility to include patients with chronic lymphocytic leukaemia based on the demonstration of the potential for GVL in this disease. 10 
